Drug Profile
Research programme: hepatitis C therapeutics - Dynavax
Alternative Names: Hepatitis C immunostimulatory DNA therapyLatest Information Update: 18 Apr 2012
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Developer Dynavax Technologies; Symphony Dynamo
- Class Oligonucleotides
- Mechanism of Action Th1 cell stimulants; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 18 Apr 2012 No development reported - Preclinical for Hepatitis C in USA (unspecified route)
- 16 Apr 2008 Preclinical trials in Hepatitis C in USA (unspecified route)
- 26 Sep 2006 Early research in Hepatitis C in USA (unspecified route)